Skip to main content Skip to main content
Go to homepage

STOP2 – Standardized Treatment of Pulmonary Exacerbations


For complete study information, view the study on

Who May Qualify?:

Patients with Cystic Fibrosis ≥ 18 years of age planned to initiate intravenous (IV) antibiotics for a pulmonary exacerbation

Who Does Not Qualify:

Patients who have been treated with IV antibiotics within 6 weeks prior to Visit 1

Study Status:
Study Sponsor:

CFFT Therapeutics Development Network Coordinating Center (TDNCC)

Full IRB Study Title:
Standardized Treatment of Pulmonary Exacerbation II (STOP2) Protocol No: STOP2-IP-15
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

For more information, contact: Brenda Bourne 330-543-3510 or Michelle Powers 330-543-3089

Lead Investigator
Gregory Omlor, MD, FAAP

Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.